BioCryst Pharmaceuticals Target of Unusually Large Options Trading (NASDAQ:BCRX)

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) saw unusually large options trading on Monday. Traders acquired 2,478 call options on the company. This is an increase of approximately 59% compared to the typical volume of 1,554 call options.

Wall Street Analysts Forecast Growth

Separately, Needham & Company LLC reissued a “buy” rating and set a $12.00 target price on shares of BioCryst Pharmaceuticals in a report on Wednesday, April 10th. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $13.83.

BioCryst Pharmaceuticals Stock Performance

Shares of BCRX opened at $5.27 on Tuesday. BioCryst Pharmaceuticals has a 52-week low of $4.03 and a 52-week high of $8.96. The business’s 50 day moving average price is $4.92 and its two-hundred day moving average price is $5.46. The firm has a market cap of $1.09 billion, a PE ratio of -4.47 and a beta of 1.96.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its earnings results on Monday, February 26th. The biotechnology company reported ($0.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.04). The firm had revenue of $93.40 million during the quarter, compared to the consensus estimate of $89.19 million. Research analysts predict that BioCryst Pharmaceuticals will post -0.69 EPS for the current fiscal year.

Institutional Investors Weigh In On BioCryst Pharmaceuticals

Several large investors have recently added to or reduced their stakes in the company. Braidwell LP grew its stake in BioCryst Pharmaceuticals by 92.1% during the third quarter. Braidwell LP now owns 5,362,980 shares of the biotechnology company’s stock valued at $37,970,000 after acquiring an additional 2,571,100 shares in the last quarter. Vanguard Group Inc. grew its holdings in shares of BioCryst Pharmaceuticals by 15.4% during the 4th quarter. Vanguard Group Inc. now owns 17,763,720 shares of the biotechnology company’s stock valued at $106,405,000 after purchasing an additional 2,371,401 shares during the last quarter. Norges Bank purchased a new position in BioCryst Pharmaceuticals in the 4th quarter worth $13,278,000. Deerfield Management Company L.P. Series C grew its stake in shares of BioCryst Pharmaceuticals by 148.6% during the third quarter. Deerfield Management Company L.P. Series C now owns 3,286,000 shares of the biotechnology company’s stock valued at $23,265,000 after buying an additional 1,964,000 shares during the last quarter. Finally, Avoro Capital Advisors LLC increased its holdings in shares of BioCryst Pharmaceuticals by 13.0% in the fourth quarter. Avoro Capital Advisors LLC now owns 13,050,000 shares of the biotechnology company’s stock worth $78,170,000 after buying an additional 1,500,000 shares during the period. Hedge funds and other institutional investors own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.